Antiretrovirals for low income countries: an analysis of the commercial viability of a highly competitive market

Table 1 **Summary of the 2010 annual reports of publicly traded Indian ARV manufacturers (*)**

	CIPLA		Ranbaxy (**)		Strides Arcolab		Aurobindo		Total of 4 companies
Gross sales of goods (minus excise duty)	61,351		56,721		16,958		39,979		175,009
Expenditure		% of expenditures		% of expenditures		% of expenditures		% of expenditures		% of expenditures
Material cost	28,604	54.1	21,709	46.2	8,508	52.4	23,286	76.9	82,107	56.1
Employee cost	4,642	8.8	7,761	16.5	2,249	13.8	3,036	10.0	17,688	12.1
Operating and other expenses	14,641	27.7	14,712	31.3	3,388	20.8	6,716	22.2	39,457	27.0
Research & Development Expenses	2,598	4.9							2,598	1.7
Interest	50	0.1	542	1.1	1,467	9.0	505	1.6	2,564	1.8
Depreciation and Amortization of goodwill	2,289	4.3	2,284	4.8	638	3.9			4,611	3.1
Total	52,824	100	47,018	100	16,250	100	30,291	100	146,383	100
		% of sales		% of sales		% of sales		% of sales		% of sales
Gross Profit before taxes	8,527	13.9	9,703	17.1	1,858	11.0	9,688	24.2	28,626	16.4

(*) Amounts in million Rupees.
(**) The expenditures of Ranbaxy exclude an extraordinary charge to account for future liabilities.

ISSN: 1744-8603